Bioxytran, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.bioxytraninc.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Bioxytran Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05733780
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
Phase 3
- Conditions
- COVID-19 PandemicCOVID-19 Respiratory InfectionSARS-CoV2 InfectionCytokine Release SyndromeCOVID-19
- Interventions
- Drug: PLACEBO
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Bioxytran Inc.
- Target Recruit Count
- 408
- Registration Number
- NCT05096052
News
No news found